Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.

Meyskens FL Jr, Simoneau AR, Gerner EW.

Recent Results Cancer Res. 2014;202:115-20. doi: 10.1007/978-3-642-45195-9_14.

PMID:
24531785
2.

Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.

Liu Z, Xu X, Li X, Liu S, Simoneau AR, He F, Wu XR, Zi X.

Cancer Prev Res (Phila). 2013 Dec;6(12):1365-75. doi: 10.1158/1940-6207.CAPR-13-0219. Epub 2013 Oct 11.

3.

Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy.

Liu Z, Li X, Simoneau AR, Jafari M, Zi X.

Mol Carcinog. 2012 Mar;51(3):257-67. doi: 10.1002/mc.20780. Epub 2011 Apr 22.

4.

Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.

Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X.

Neoplasia. 2011 Feb;13(2):108-19.

5.

The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition.

Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH, Zi X.

Mol Cancer. 2010 Jun 23;9:162. doi: 10.1186/1476-4598-9-162.

7.

WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.

Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X.

Mol Cancer Ther. 2009 Feb;8(2):458-68. doi: 10.1158/1535-7163.MCT-08-0885. Epub 2009 Jan 27.

8.

Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.

Tang Y, Simoneau AR, Xie J, Shahandeh B, Zi X.

Cancer Prev Res (Phila). 2008 Nov;1(6):439-51. doi: 10.1158/1940-6207.CAPR-08-0165.

9.

Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy.

Narayanan R, Werahera PN, Barqawi A, Crawford ED, Shinohara K, Simoneau AR, Suri JS.

Phys Med Biol. 2008 Oct 21;53(20):N397-406. doi: 10.1088/0031-9155/53/20/N03. Epub 2008 Sep 30.

PMID:
18827317
10.

Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer.

Shen F, Shinohara K, Kumar D, Khemka A, Simoneau AR, Werahera PN, Li L, Guo Y, Narayanan R, Wei L, Barqawi A, Crawford ED, Davatzikos C, Suri JS.

J Ultrasound Med. 2008 Jun;27(6):895-905. Review.

11.

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.

12.
15.

Continent lower urinary tract reconstruction in the cervical spinal cord injured population.

Zommick JN, Simoneau AR, Skinner DG, Ginsberg DA.

J Urol. 2003 Jun;169(6):2184-7.

PMID:
12771745
16.

Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial.

Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr.

J Natl Cancer Inst. 2001 Jan 3;93(1):57-9. No abstract available.

17.

Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial.

Chancellor MB, Bennett C, Simoneau AR, Finocchiaro MV, Kline C, Bennett JK, Foote JE, Green BG, Martin SH, Killoran RW, Crewalk JA, Rivas DA.

J Urol. 1999 Jun;161(6):1893-8.

PMID:
10332461
18.

Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.

Simoneau AR, Spruck CH 3rd, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA.

Cancer Res. 1996 Nov 1;56(21):5039-43.

19.

Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy.

Formenti SC, Lieskovsky G, Simoneau AR, Skinner D, Groshen S, Chen SC, Petrovich Z.

J Urol. 1996 Feb;155(2):616-9.

PMID:
8558674
20.

Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction.

Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG.

Cancer. 1995 Sep 1;76(5):833-9.

PMID:
8625187
21.

Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium.

Tsai YC, Simoneau AR, Spruck CH 3rd, Nichols PW, Steven K, Buckley JD, Jones PA.

J Urol. 1995 May;153(5):1697-700.

PMID:
7715013
22.
23.

p16 gene in uncultured tumours.

Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA.

Nature. 1994 Jul 21;370(6486):183-4. No abstract available.

PMID:
8028660
24.

Bladder cancer: the molecular progression to invasive disease.

Simoneau AR, Jones PA.

World J Urol. 1994;12(2):89-95. Review.

PMID:
7916240
25.

Re: Erotic erection versus nocturnal erection.

Goldstein AM, Simoneau AR.

J Urol. 1991 Jun;145(6):1278-9. No abstract available.

PMID:
2033715

Supplemental Content

Loading ...
Support Center